Mónica García‐Álvarez, Daniel Pineda‐Tenor, María A. Jiménez‐Sousa, Amanda Fernández‐Rodríguez, María Guzmán‐Fulgencio, Salvador Resino – 27 June 2014 – There is growing evidence that vitamin D is related to chronic hepatitis C (CHC) pathogenicity. We analyzed the relationship of vitamin D status with advanced liver fibrosis (ALF) in CHC treatment‐naïve patients and sustained virologic response (SVR) in CHC patients on pegylated interferon alpha plus ribavirin (pegIFNα/ribavirin) therapy.

Anna Hadjihambi, Christopher F. Rose, Rajiv Jalan – 27 June 2014

Adam Pennycuick, Abid R. Suddle, Augusto Villanueva – 27 June 2014

Jean‐François Dufour – 26 June 2014

Jean‐François Dufour – 26 June 2014

Shadi Abu‐Hayyeh, Catherine Williamson – 26 June 2014

Benoit Callendret, Heather B. Eccleston, Shelby Hall, William Satterfield, Stefania Capone, Antonella Folgori, Riccardo Cortese, Alfredo Nicosia, Christopher M. Walker – 26 June 2014

Suzanne Rose, Oren K. Fix, Brijen J. Shah, Tamara N. Jones, Ronald D. Szyjkowski – 26 June 2014

Petra Hirsova, Gregory J. Gores – 26 June 2014

Masatoshi Ishigami, Takashi Honda, Yoji Ishizu, Yasuharu Onishi, Hideya Kamei, Kazuhiko Hayashi, Yasuhiro Ogura, Yoshiki Hirooka, Hidemi Goto – 25 June 2014 – The combination of nucleos(t)ide analogues (NAs) and hepatitis B immune globulin has been established as safe and effective prophylaxis against hepatitis B virus (HBV) reactivation after liver transplantation (LT). However, the essential weak point of this regimen is its high cost.